Literature DB >> 19285828

Quantitative intra-operative assessment of peritoneal carcinomatosis - a comparison of three prognostic tools.

H A M Swellengrebel1, F A N Zoetmulder, R M Smeenk, N Antonini, V J Verwaal.   

Abstract

AIMS: Selecting patients for cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy (HIPEC) remains challenging. We compared the predictive power of three intra-operative assessment tools of peritoneal involvement of colorectal cancer.
METHODS: Ninety-two procedures (1999-2005) were prospectively scored using the Simplified Peritoneal Cancer Index (SPCI) and 7 Region Count. The Peritoneal Cancer Index (PCI) was retrospectively scored using the SPCI tool, operative notes and pathological reports. Endpoints were completeness of cytoreduction and overall survival. Logistic regression and Receiver Operating Characteristic (ROC) curves were applied to compare the predictive value of the three scoring systems on completeness of cytoreduction.
RESULTS: After a median follow-up of 31 months, the median overall survival was 25.6 months. It decreased to 7.3 months, when cytoreduction was incomplete (p=0.001). An increased PCI, SPCI or number of regions were all associated with a decrease in probability of complete cytoreduction (p<0.05). With complete cytoreduction as outcome, the ROC areas for the PCI, SPCI and 7 Region Count were 0.92, 0.94 and 0.90, respectively (p=0.14). Using a cut-off value of 16 in the PCI system (p=0.03), 13 in the SPCI system (p=0.04) and 6 regions in the 7 Region Count (p=0.0002) the probability of complete cytoreduction decreased significantly.
CONCLUSION: The PCI, SPCI and 7 Region Count are useful and equally effective prognostic tools predicting completeness of cytoreduction and associated improved survival. The 7 Region Count may be preferred due to its practical simplicity.

Entities:  

Mesh:

Year:  2009        PMID: 19285828     DOI: 10.1016/j.ejso.2009.02.010

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  13 in total

1.  Correlation of Radiologic with Surgical Peritoneal Cancer Index Scores in Patients with Pseudomyxoma Peritonei and Peritoneal Carcinomatosis: How Well Can We Predict Resectability?

Authors:  Kristina Flicek; Awais Ashfaq; C Dan Johnson; Christine Menias; Sanjay Bagaria; Nabil Wasif
Journal:  J Gastrointest Surg       Date:  2015-07-11       Impact factor: 3.452

2.  Impact of a modified peritoneal cancer index using FDG-PET/CT (PET-PCI) in predicting tumor grade and progression-free survival in patients with pseudomyxoma peritonei.

Authors:  Masatoshi Hotta; Ryogo Minamimoto; Yoshimasa Gohda; Toru Igari; Hideaki Yano
Journal:  Eur Radiol       Date:  2019-03-14       Impact factor: 5.315

3.  Malignant peritoneal mesothelioma: prognostic factors and oncologic outcome analysis.

Authors:  Deepa Magge; Mazen S Zenati; Frances Austin; Arun Mavanur; Magesh Sathaiah; Lekshmi Ramalingam; Heather Jones; Amer H Zureikat; Matthew Holtzman; Steven Ahrendt; James Pingpank; Herbert J Zeh; David L Bartlett; Haroon A Choudry
Journal:  Ann Surg Oncol       Date:  2013-12-10       Impact factor: 5.344

4.  Current Management of Peritoneal Carcinomatosis From Colorectal Cancer: The Role of Cytoreductive Surgery and Hyperthermic Peritoneal Chemoperfusion.

Authors:  Ibrahim Nassour; Patricio M Polanco
Journal:  Curr Colorectal Cancer Rep       Date:  2017-04-08

Review 5.  Peritoneal Carcinomatosis from Colon Cancer: A Systematic Review of the Data for Cytoreduction and Intraperitoneal Chemotherapy.

Authors:  Ashlie Nadler; J Andrea McCart; Anand Govindarajan
Journal:  Clin Colon Rectal Surg       Date:  2015-12

6.  Factors influencing long-term survival after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei originating from appendiceal neoplasms.

Authors:  W J van Eden; N F M Kok; P Snaebjornsson; K Jóźwiak; K Woensdregt; P D Bottenberg; H Boot; A G J Aalbers
Journal:  BJS Open       Date:  2019-02-19

7.  Clinical course for patients with peritoneal carcinomatosis excluded from cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.

Authors:  Anne Peen Rodt; Rebekka Oxenvad Svarrer; Lene Hjerrild Iversen
Journal:  World J Surg Oncol       Date:  2013-09-16       Impact factor: 2.754

8.  Computerized System for Staging Peritoneal Surface Malignancies.

Authors:  Paolo Sammartino; Daniele Biacchi; Tommaso Cornali; Fabio Accarpio; Simone Sibio; Bernard Luraschi; Alessio Impagnatiello; Angelo Di Giorgio
Journal:  Ann Surg Oncol       Date:  2015-11-12       Impact factor: 5.344

Review 9.  Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy improves survival for peritoneal carcinomatosis from colorectal cancer: a systematic review and meta-analysis of current evidence.

Authors:  Chao-Qun Huang; Yao Min; Shu-Yi Wang; Xiao-Jun Yang; Yang Liu; Bin Xiong; Yutaka Yonemura; Yan Li
Journal:  Oncotarget       Date:  2017-04-27

10.  Preclinical activity of melflufen (J1) in ovarian cancer.

Authors:  Charlotte Carlier; Sara Strese; Kristina Viktorsson; Ebba Velander; Peter Nygren; Maria Uustalu; Therese Juntti; Rolf Lewensohn; Rolf Larsson; Jack Spira; Elly De Vlieghere; Wim P Ceelen; Joachim Gullbo
Journal:  Oncotarget       Date:  2016-09-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.